Clinical Trial Update: RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating RC48 (disitamab vedotin) combined with Adebrelimab, Apatinib, and S-1 as neoadjuvant therapy for locally advanced gastric canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Adebrelimab (adebrelimab)
• Apatinib (apatinib)
• RC48 (disitamab vedotin)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Gastric Cancer/Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING